Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

Figure 4

Effects of RAD001, AEE788 or erlotinib versus drug combination on kidney cancer proliferation in vitro. A498, Caki-1 or KTC-26 cells were treated with 1 nM RAD001, 1 μM AEE788 or 1 μM erlotinib, applied alone or in combination. Controls remained untreated. Cells were then counted after a further 24, 48 and 72 h using the MTT dye reduction assay. One representative of 6 experiments is shown. * indicates significant difference to controls (p < 0.05).

Back to article page